Kamm, Christian P; Mattle, Heinrich P (2009). SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. Trials, 10, p. 115. London: BioMed Central 10.1186/1745-6215-10-115
|
Text
1745-6215-10-115.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (337kB) | Preview |
Statins have anti-inflammatory and immunomodulatory properties in addition to their lipid-lowering effects. Currently, the effects of statins on multiple sclerosis are still controversial. Therefore, randomized clinical trials are needed to provide better evidence on the therapeutic potential of statins in multiple sclerosis. The SWiss Atorvastatin and Interferon Beta-1b trial in Multiple Sclerosis (SWABIMS) evaluates the efficacy, safety and tolerability of atorvastatin 40 mg per os daily and subcutaneous interferon beta-1b every other day compared to monotherapy with subcutaneous interferon beta-1b every other day in patients with relapsing-remitting multiple sclerosis.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Kamm, Christian Philipp, Mattle, Heinrich |
ISSN: |
1745-6215 |
Publisher: |
BioMed Central |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 15:14 |
Last Modified: |
05 Dec 2022 14:22 |
Publisher DOI: |
10.1186/1745-6215-10-115 |
PubMed ID: |
20003436 |
Web of Science ID: |
000273286900001 |
BORIS DOI: |
10.7892/boris.32430 |
URI: |
https://boris.unibe.ch/id/eprint/32430 (FactScience: 197611) |
Actions (login required)
 |
Edit item |